GH Research PLC (NASDAQ:GHRS) Receives Average Recommendation of “Moderate Buy” from Brokerages

GH Research PLC (NASDAQ:GHRS) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $40.3750.

GHRS has been the subject of a number of research reports. Citigroup reiterated an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Needham & Company LLC increased their price objective on GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Cantor Fitzgerald increased their price objective on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. HC Wainwright decreased their price objective on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently modified their holdings of the stock. Lynx1 Capital Management LP grew its stake in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter. RTW Investments LP grew its stake in shares of GH Research by 6.5% in the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after acquiring an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of GH Research in the fourth quarter worth $22,860,000. Troluce Capital Advisors LLC grew its stake in shares of GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of GH Research by 324.1% in the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock worth $12,350,000 after acquiring an additional 659,957 shares during the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Trading Up 7.2%

GHRS opened at $23.99 on Friday. The stock has a fifty day simple moving average of $18.54 and a two-hundred day simple moving average of $16.14. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -26.08 and a beta of 1.27. GH Research has a 12-month low of $10.96 and a 12-month high of $24.66.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, analysts predict that GH Research will post -1.46 EPS for the current year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.